A phase II trial of erlotinib for EGFR mutant NSCLC to prospectively assess biopsy feasibility and acquired resistance at disease progression

Category Primary study
JournalJournal of Clinical Oncology
Year 2015
This article has no abstract
Epistemonikos ID: f12ec011429aa388d03e822758a9e28926c21222
First added on: Feb 07, 2025